News
Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Novo Nordisk shares fell significantly due to pressure from U.S. President Donald Trump to cut drug prices, and competition ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.
WFRV Local 5 on MSN1d
New tariffs could raise prices of Ozempic, WegovySome of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback